Soligenix (SNGX) Stock Soars 110% as Ebola Outbreak Puts Vaccine Hopes on the Table

TLDR

• Soligenix stock surged over 110% in pre-market trading Wednesday after the company announced its ThermoVax platform could rapidly develop a Bundibugyo virus vaccine.
• The WHO declared the ongoing DRC Ebola outbreak a Public Health Emergency of International Concern, with over 900 suspected infections and 223 suspected deaths reported.
• No approved vaccines currently exist for Bundibugyo, Sudan, or Marburg viruses — a gap Soligenix says its platform is positioned to fill.
• Soligenix’s filovirus vaccines have shown 100% protection in non-human primates and can remain stable for two years at 40°C, eliminating the need for cold-chain storage.
• Short interest in SNGX is at a six-month high, and the stock has declined over 63% year-to-date prior to this week’s rally.

Soligenix (SNGX) stock closed the regular session Tuesday up 31.5% at $0.51, then surged another 72% in after-hours trading before spiking more than 110% in pre-market Wednesday. The stock is on pace to reclaim the $1 level for the first time in a month.

Soligenix, Inc., SNGX

The move came after Soligenix announced its ThermoVax platform could be used to quickly develop a thermostable vaccine for Bundibugyo virus — one of the strains behind the current Ebola outbreak in the Democratic Republic of Congo.

The DRC outbreak has recorded over 900 suspected infections and 223 suspected deaths as of May 2026. The World Health Organization classified the situation as a public health emergency of international concern earlier this month.

Two confirmed cases have already spread into neighboring Uganda, with WHO’s Africa regional director warning of cross-border transmission risk.

Soligenix developed its vaccine formulations in partnership with the University of Hawaii. Professor Axel Lehrer, who collaborated on the project, said the vaccines showed 100% protection in non-human primate studies.

The vaccines can be stored for at least two years at 40°C (104°F), which is a practical advantage for distribution in endemic regions where cold-chain infrastructure is limited.

No Approved Vaccines for Key Filoviruses

There are currently no approved vaccines for Bundibugyo virus, Sudan virus, or Marburg virus. That gap is central to the market’s reaction to Soligenix’s announcement.

Soligenix CEO Christopher J. Schaber said the ThermoVax platform has already successfully stabilized vaccines for ricin toxin, Ebola, Sudan, Marburg, and COVID. The company says the platform can induce broad immune coverage and compete with technologies that require cold-chain storage.

Soligenix also holds FDA Orphan Drug Designations for Sudan and Marburg viruses. Those designations come with seven-year market exclusivity, eligibility for federal grants to fund clinical trials, and a waiver of FDA user fees on Biologics License Application submission.

Retail Interest and Short Squeeze Risk

Retail sentiment on Stocktwits flipped to “extremely bullish” from “bullish” within 24 hours, and chatter volume on the stock jumped roughly 14,000% over a seven-day period.

Short interest in SNGX is currently at a six-month high according to Koyfin data, raising the possibility that part of the price action reflects a short squeeze.

SNGX is also approaching the 100-day moving average, a technical level it has not traded above in a month. Resistance has been flagged by retail traders in the $1.13–$1.15 range.

The stock has a market cap of approximately $7.61 million and a 52-week range of $0.28 to $6.23. Over the past 12 months, SNGX has dropped 73%.

The CDC has called for tighter screening of travelers arriving from affected DRC and Uganda regions, keeping the outbreak in the news cycle.

The post Soligenix (SNGX) Stock Soars 110% as Ebola Outbreak Puts Vaccine Hopes on the Table appeared first on CoinCentral.